ResearcherCarl von Ossietzky Universität OldenburgActive in the last 2 years

Gaetan Aime Noubissi Nzeteu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2859-9054; OpenAlex author ID A5016018123. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. First author DOI 10.3389/fimmu.2025.1495907 ↗
Nanoparticle-based immunotherapy of pancreatic cancer. Co-author DOI 10.3389/fmolb.2022.948898 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Maximilian Bockhorn · 2 shared papers, 2022–2025 · strength 0.47
- Paper It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1495907 ↗
- Paper Nanoparticle-based immunotherapy of pancreatic cancer. DOI 10.3389/fmolb.2022.948898 ↗
N. Helge Meyer · 2 shared papers, 2022–2025 · strength 0.47
- Paper It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1495907 ↗
- Paper Nanoparticle-based immunotherapy of pancreatic cancer. DOI 10.3389/fmolb.2022.948898 ↗
Christin Knickmeier · 1 shared paper, 2025 · strength 0.28
- Paper It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1495907 ↗
Maarten W. Nijkamp · 1 shared paper, 2025 · strength 0.28
- Paper It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1495907 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.